Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
NCT04116359 · National Cancer Institute (NCI) · PHASE1/PHASE2 · withdrawn · last registry update 2020-09-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Other - Protocol moved to Disapproved” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-28Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT05058651)
- 2021-06-03Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT01856192)
- 2021-06-01Results posted on the registry: Takeda, Brentuximab vedotin + Doxorubicin (NCT02979522)
- 2021-03-16Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04799275)
- 2021-03-12Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cediranib Maleate (NCT02446600)
- 2021-02-18Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04759586)
- 2021-01-28Phase 3 first posted: Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2020-12-14Phase 3 first posted: Hoffmann-La Roche, Tiragolumab + Atezolizumab (NCT04665856)
- 2020-11-16Phase 3 first posted: National Cancer Institute (NCI), Cisplatin + Doxorubicin Hydrochloride (NCT04628767)
- 2020-11-13Phase 3 first posted: University of Ulm, Venetoclax + Placebo (NCT04628026)
- 2020-11-10Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab 200 mg + Pembrolizumab 400 mg (NCT04624204)
- 2020-09-07Phase 3 first posted: Latin American Cooperative Oncology Group, Docetaxel or Paclitaxel + Cyclophosphamide + Doxorrubicin (NCT04540692)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
- 2020-08-28Phase 3 first posted: Acerta Pharma BV, acalabrutinib + placebo (NCT04529772)
- 2020-08-24Results posted on the registry: Massachusetts General Hospital, Brentuximab Vedotin + Adriamycin (NCT02505269)
- 2020-03-13Phase 3 first posted: Institut Claudius Regaud, Standard of care + chemotherapy (NCT04307277)
- 2020-03-03Phase 3 first posted: Children's Oncology Group, Asparaginase Erwinia chrysanthemi + Cytarabine (NCT04293562)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision